- November 22, 2026
- Updated 8:16 am
New Pancreatic Cancer Drug Doubles Survival Time
- 20 Views
- admin
- November 21, 2026
- Health Medical Research
A new drug called Rasonque shows promise for treating pancreatic cancer, extending median survival for stage 4 patients to 13.2 months. This compares to only 6.7 months with standard chemotherapy, offering renewed hope for patients with an historically low survival rate.
Researchers shared early trial results of an experimental pill combined with standard chemotherapy at the EORTC-NCI-AACR Symposium in Barcelona. The study suggests potential benefits for advanced pancreatic cancer patients, typically facing a 3% five-year survival rate.
Clinical Trial Success
The phase 1/2 trial of the oral medication, daraxonrasib, tested alongside the chemotherapy drugs gemcitabine and nab-paclitaxel, included 61 patients with metastasized pancreatic cancer. They had not received prior treatment for this advanced stage.
Findings show that 90.2% of patients experienced tumor shrinkage or halted growth. In 60.7% of cases, tumor size decreased, and they vanished completely in 8.2% of patients.
Extending Survival
Patients in the trial went 12.8 months on average before worsening, nearly doubling the timeframe with standard chemotherapy. At one year, 76.6% of participants remained alive.
Dr. Wungki Park from Memorial Sloan Kettering Cancer Center highlighted substantial tumor reductions and prolonged disease control. Only 5% stopped treatment due to side effects, mainly rash, diarrhea, fatigue, and low blood cell counts, which were manageable.
Impact of RAS-targeted Drug
A defective RAS gene triggers the growth of pancreatic tumors. Daraxonrasib targets this, aimed at halting the signal believed unmanageable through medication. Dr. Elena Garralda from the Vall d’Hebron Institute of Oncology noted the combination’s potential for longer-lasting outcomes.
Further Research
Limitations exist, as the study lacked a comparison group receiving only standard chemotherapy. Researchers have begun a phase 3 trial, RASolute-303, to compare daraxonrasib alone and combined with chemotherapy against standard treatment.
Funding for daraxonrasib development comes from Revolution Medicines.